scholarly journals Clinical outcomes and satisfaction of autologous serum tears treatment for ocular surface diseases

2022 ◽  
Vol 100 (S267) ◽  
Author(s):  
Itzel Aguilar‐Valdez ◽  
Paola De La Parra‐Colin ◽  
Jesús Luna‐Briceño
Keyword(s):  
Clinical Outcomes ◽  
Ocular Surface ◽  
Autologous Serum ◽  
Ocular Surface Diseases

scholarly journals Use of Acellular Umbilical Cord-Derived Tissues in Corneal and Ocular Surface Diseases

Medicines ◽  
2021 ◽  
Vol 8 (2) ◽  
pp. 12
Author(s):  
Arianna A. Tovar ◽  
Ian A. White ◽  
Alfonso L. Sabater
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Ocular Surface ◽  
Cellular Proliferation ◽  
Mononuclear Cells ◽  
Autologous Serum ◽  
High Concentration ◽  
Ocular Surface Diseases ◽  
Natural Healing

Blood derived products have become a valuable source of tissue for the treatment of ocular surface diseases that are refractory to conventional treatments. These can be obtained from autologous or allogeneic sources (patient’s own blood or from healthy adult donors/umbilical cord blood, respectively). Allogeneic cord blood demonstrates practical advantages over alternatives and these advantages will be discussed herein. Umbilical cord blood (UCB) can be divided, generally speaking, into two distinct products: first, mononuclear cells, which can be used in regenerative ophthalmology, and second, the plasma/serum (an acellular fraction), which may be used in the form of eyedrops administered directly to the damaged ocular surface. The rationale for using umbilical cord serum (UCS) to treat ocular surface diseases such as severe dry eye syndrome (DES), persistent epithelial defects (PED), recurrent epithelial erosions, ocular chemical burns, graft versus host disease (GVHD), among others, is the considerably high concentration of growth factors and cytokines, mimicking the natural healing properties of human tears. Allogeneic serum also offers the opportunity for therapeutic treatment to patients who, due to poor heath, cannot provide autologous serum. The mechanism of action involves the stimulation of endogenous cellular proliferation, differentiation and maturation, which is highly efficient in promoting and enhancing corneal epithelial healing where other therapies have previously failed.

scholarly journals Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops

2020 ◽  
Vol 9 (12) ◽  
pp. 3904
Author(s):  
Ha-Rim So ◽  
Hae Young Lopilly Park ◽  
So-Hyang Chung ◽  
Hyun-Seung Kim ◽  
Yong-Soo Byun
Keyword(s):  
Ocular Surface ◽  
Ocular Surface Disease ◽  
Autologous Serum ◽  
Ocular Surface Disease Index ◽  
Ocular Surface Diseases ◽  
Group 3 ◽  
Baseline Values ◽  
Group 2 ◽  
Group 1

Autologous serum eyedrops (ASE) are effective in treating various ocular surface diseases, including damages induced by long-term use of preserved glaucoma eyedrops. However, there has been no study on whether ASE is effective without stopping the causative eyedrops. This retrospective observational study included 55 patients with ocular-surface diseases caused by long-term use of preserved glaucoma eyedrops: 18 patients who used ASEs for 2 months without discontinuing the use of glaucoma eyedrops (Group 1), 22 patients who used ASEs for 2 months, discontinuing the use of glaucoma eyedrops for the first month (Group 2) and 15 patients who used non-preservative artificial tears for 2 months, discontinuing the use of glaucoma eyedrops for the first month (Group 3). There were no intergroup differences in the baseline values of the Schirmer I test results, tear breakup time (TBUT), ocular surface staining (OSS) score, loss of the meibomian gland, meibum quality and ocular-surface disease index (OSDI). Group 1 showed significant differences in TBUT, OSS score and OSDI at 2 months when compared to the baseline values before treatment, while Group 2 showed significant differences in those values at both 1 and 2 months. There were no differences in any of the parameters at baseline, 1 month or 2 months in Group 3. Our result suggested that ASE is effective for treating ocular surface diseases caused by glaucoma eyedrops containing preservatives and its effects can be expected without interruption of glaucoma eyedrop treatment.

scholarly journals Autologous serum for ocular surface diseases

2008 ◽  
Vol 71 (6) ◽  
pp. 47-54 ◽  
Author(s):  
Guilherme Goulart Quinto ◽  
Mauro Campos ◽  
Ashley Behrens
Keyword(s):  
Ocular Surface ◽  
Autologous Serum ◽  
Ocular Surface Diseases

Contamination Risk of 100% Autologous Serum Eye Drops in Management of Ocular Surface Diseases

Cornea ◽  
2013 ◽  
Vol 32 (8) ◽  
pp. 1116-1119 ◽  
Author(s):  
Onsiri Thanathanee ◽  
Warachaya Phanphruk ◽  
Orapin Anutarapongpan ◽  
Amornrat Romphruk ◽  
Olan Suwan-apichon
Keyword(s):  
Ocular Surface ◽  
Autologous Serum ◽  
Eye Drops ◽  
Contamination Risk ◽  
Ocular Surface Diseases ◽  
Serum Eye Drops

Amniotic membrane extract eye drops for ocular surface diseases: use and clinical outcome in real-world practice

2021 ◽  
Author(s):  
Noelia Sabater-Cruz ◽  
◽  
Marc Figueras-Roca ◽  
Miriam Ferrán-Fuertes ◽  
Elba Agustí ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Amniotic Membrane ◽  
Real World ◽  
Ocular Surface ◽  
Eye Drops ◽  
Ocular Surface Diseases ◽  
Membrane Extract

Ocular surface diseases and corneal refractive surgery

2014 ◽  
Vol 25 (4) ◽  
pp. 264-269 ◽  
Author(s):  
Debora Garcia-Zalisnak ◽  
David Nash ◽  
Elizabeth Yeu
Keyword(s):  
Ocular Surface ◽  
Refractive Surgery ◽  
Ocular Surface Diseases ◽  
Corneal Refractive Surgery

scholarly journals Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e048479
Author(s):  
Passara Jongkhajornpong ◽  
Pawin Numthavaj ◽  
Thunyarat Anothaisintawee ◽  
Kaevalin Lekhanont ◽  
Gareth McKay ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Platelet Rich Plasma ◽  
Controlled Trial ◽  
Dry Eye Disease ◽  
Autologous Serum ◽  
Eye Disease ◽  
Eye Drops ◽  
Department Of Ophthalmology ◽  
Autologous Platelet

IntroductionDry eye disease (DED) is a common eye problem. Although the disease is not fatal, it substantially reduces quality of life and creates a high economic burden, especially in patients with moderate-to-severe DED. Several biological tear substitutes (eg, autologous serum (AS), autologous platelet-rich plasma (APRP) and autologous platelet lysate) could effectively improve dry eyes. However, evidence on their comparative efficacy is controversial. This study aims to compare the efficacy of 100% APRP with 100% AS eye drops in patients with moderate-to-severe DED.Methods and analysisThe study is a single-centre, double-blinded randomised, parallel, non-inferiority trial. One hundred and thirty patients with moderate-to-severe DED, aged 18–70 years will be recruited from outpatient clinic, Department of Ophthalmology, Ramathibodi Hospital, Bangkok from February 2021 to January 2023. Patients will be randomised to receive either 100% APRP or 100% AS eye drops (1:1 ratio) for 4 weeks. The primary outcomes are ocular surface disease index (OSDI) and ocular surface staining (OSS) evaluated using the Oxford scale. Secondary outcomes are fluorescein break-up time, Schirmer’s I test, meibomian gland parameters and adverse events. Other measured outcomes include best-corrected visual acuity, intraocular pressure and compliance.Ethics and disseminationThe study protocol and any supplements used in conducting this trial have been approved by the Ethics Committee of Faculty of Medicine, Ramathibodi Hospital, Mahidol University (MURA2020/1930). Informed consent will be obtained from all patients before study entry. Results will be presented in peer-reviewed journals and international conferences.Trial registration numberNCT04683796.

Smog analysis and its effect on reported ocular surface diseases: A case study of 2016 smog event of Lahore

2019 ◽  
Vol 198 ◽  
pp. 257-264 ◽  
Author(s):  
Arooj Ashraf ◽  
Aleem Butt ◽  
Imran Khalid ◽  
Rao Umair Alam ◽  
Sajid Rashid Ahmad
Keyword(s):  
Ocular Surface ◽  
Ocular Surface Diseases
Sign in / Sign up

Export Citation Format

Share Document